Hepatitis C virus infection: Co-infection with HIV and HBV

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 2, 2000, Pages 265-275

  Cropley, Ian ^b   Main, Janice ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NONE

Author keywords

Hepatitis B; Hepatitis C; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; INTERFERON; LAMIVUDINE; RIBAVIRIN; ZIDOVUDINE;

COMORBIDITY; DISEASE COURSE; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIVER FIBROSIS; LYMPHOCYTE COUNT; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SURVIVAL RATE; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0034047176     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0075     Document Type: Article

References (55)

1. Morbidity and Mortality Weekly Report. 48:1999;1-59.
2. Schoeman M N, Liddle C, Bilous M. Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity and effects of immunosuppressive therapy on disease. Australian and New Zealand Journal of Medicine. 20:1990;56-62.
3. Cribier B, Schmitt C, Rey D. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Research in Virology. 147:1996;263-267.
4. Woitas R P, Rockstroh J K, Beier I. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS. 13:1999;1313-1322.
5. Martin P, Di Bisceglie A M, Kassianides C. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology. 97:1989;1559-1561.
6. Wright T L, Hollander H, Pu X. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology. 20:1994;1152-1155.
7. Dorruci M, Pezzotti P, Phillips A N, Lepri A C, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian seroconversion study. Journal of Infectious Diseases. 172:1995;1503-1508.
8. Eyster M E, Diamondstone L S, Jau-Min L. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndrome. 6:1993;602-610.
9. Telfer P, Sabin C, Devereux H. The progression of HCV-associated liver disease in a cohort of haemophiliac patients. British Journal of Haematology. 87:1994;555-561.
10. Soto B, Sanchez-Quijano A, Rodrigo L. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology. 26:1997;1-5.
11. Darby S C, Ewart D A, Giangrande P CF. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet. 350:1997;1425-1431.
12. Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients. Hepatology. 30:1999;1054-1058.
13. Pechere M, Krischer J, Rosay A, Hirschel B, Saurat J-H. Red fingers syndrome in patients with HIV and hepatitis C infection. Lancet. 348:1996;196-197.
14. Cohen P, Roulot D, Ferriere F. Prevalence of cryoglobulins and hepatitis C virus infection in HIV-infected patients. Clinical and Experimental Rheumatology. 15:1997;523-527.
15. Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood. 84:1994;1020-1023.
16. Telfer P T, Brown D, Devereux H, Lee C A, Dusheiko G M. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophiliac patients. British Journal of Haematology. 88:1994;397-399.
17. Ohto H, Terazawa S, Sasaki N. Transmission of hepatitis C virus from mothers to infants. New England Journal of Medicine. 330:1994;744-750.
18. Eyster M E, Alter H J, Aledort L M. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency (HIV). Annals of Internal Medicine. 115:1991;764-768.
19. Chamot E, Hirchel B, Wintsch J, Francois-Robert C. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS. 4:1990;1275-1277.
20. Boyer N, Marcellin P, Degon C. Recombinant interferon alpha for chronic hepatitis C in patients coinfected with the human immunodeficiency virus. Journal of Infectious Diseases. 165:1992;723-726.
21. Marriott E, Navas S, del-Romeros J. Treatment with recombinant alpha interferon of chronic hepatitis C in HIV-positive patients. Journal of Medical Virology. 40:1993;107-111.
22. Soriano V, Garcia-Samaniego J, Bravo R. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish study group. Clinical Infectious Diseases. 23:1996;585-591.
23. Soriano V, Bravo R, Garcia-Samaniego J. Relapes of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS. 11:1997;400-401.
24. +cells after IFN α treatment in HIV-1 infection. Lancet. 341:1993;958-959.
25. Pesce A, Taillan B, Rosenthal E. Opportunistic infection and CD4 lymphopenia with interferon treatment in HIV-1 infected patients. Lancet. 341:1993;1597.
26. Soriano V, Garcia-Samaniego J, Bravo R. Efficacy and safety of alpha interferon treatment for chronic hepatitis C in HIV infected patients. Journal of Infection. 31:1995;9-13.
27. McCormick J B, Getchell J P, Mitchell S W, Hicks D R. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T-lymphocytes. Lancet. 15:1984;1367-1369.
28. Vogt M W, Hartshorn K L, Furman P A. Ribavirin antagonises the effect of azidothymidine on HIV replication. Science. 235:1987;1376-1379.
29. Baba M R, Pauwels J, Balzarini P. Ribavirin antagonises inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy. 31:1987;1613-1617.
30. Hoggard P G, Barry M G, Khoo S H, Back D J. Drug interactions with d4T phosphorylation in vitro. British Journal of Pharmacology. 42:1996;278.
31. Soriano, V, Garcia-Samaniego, J, Perez-Olmeda, M, Gonzalez, J, Efficacy and safety of interferon plus ribavirin for chronic hepatitis C in HIV-infected patients, 1998.
32. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS. 13:1999;539-546.
33. Dieterich, D, Weisz, K, Goldman, A, Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV co-infected patients, 1999.
34. Landau, A, OL, Batisse, D, Duong van Huten, J, P, Efficacy of combination therapy with interferon alpha-2b and ribavirin for chronic hepatitis C in HIV-infected patients, 1999.
35. Garcia-Samaniego J, Bravo R, Castilla J. Lack of benefit of protease inhibitors on HCV viraemia in HIV-infected patients. Journal of Hepatology. 28:1998;526-527.
36. Rockstroh J K, Theisen A, Kaiser R, Sauerbach T, Spengler U. Antiretroviral triple therapy decreases HIV-viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-/HIV-coinfected hemophiliacs. AIDS. 12:1998;829-830.
37. Rutschmann O T, Negro F, Hirschel B. Impact of treatment with human immunodeficiency (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. Journal of Infectious Diseases. 177:1998;783-785.
38. Chu C M, Sheen I S, Liaw Y F. The role of hepatitis C virus in fulminant viral hepatitis in an endemic area of hepatitis A and B. Gastroenterology. 107:1994;189-195.
39. Wu J C, Chen C L, Hou M C. Multiple viral infection as the most common cause of fulminant and sub-fulminant viral hepatitis in an area endemic for hepatitis B: application and limitation of the polymerase chain reaction. Hepatology. 19:1994;836-840.
40. Mimms L T, Mosely J W, Hollinger F B. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. British Medical Journal. 307:1993;1095-1097.
41. Doi T, Yamada G, Endo H. Hepatitis type C virus infection in patients with type B chronic liver disease. Gastroenterology Japan. 27:1992;617-623.
42. Crespo J, Lozano J L, de la Cruz F. Prevalence and significance of hepatitis C viraemia in chronic active hepatitis B. American Journal of Gastroenterology. 89:1994;1147-1151.
43. Weltman M D, Brotodihardjo A, Crewe E B. Coinfection with hepatitis B and C or B,C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. Journal of Viral Hepatitis. 2:1995;39-45.
44. Chiaramonte M, Stroffolini T, Vian A. Rate of incidence of hepatocellular carcinoma in patients with compensated cirrhosis. Cancer. 85:1999;2132-2137.
45. Ruiz J, Sangro B, Cuende J I. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology. 16:1992;637-641.
46. Shiratori Y, Shiina S, Zhang P Y. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer. 80:1997;2060-2067.
47. Kew M C, Yu M C, Kedda M A. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology. 112:1997;184-187.
48. Huang E J, Wright T L, Lake J R, Combs C, Ferrell L D. Hepatitis B and C coinfections and persistent hepatitis B infection: clinical outcome and liver pathology after transplantation. Hepatology. 23:1996;396-404.
49. Sato S, Fujiyama S, Tanaka M. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. Journal of Hepatology. 21:1994;159-166.
50. Pontisso P, Ruvoletto M G, Fattovich G. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 105:1993;1529-1533.
51. Fukuda R, Ishimura N, Niigaki M. Serological silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. Journal of Medical Virology. 58:1999;201-207.
52. Guido M, Thung S N, Fattovich G. Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Modern Pathology. 12:1999;599-603.
53. Uchida T, Kaneita Y, Gotoh K. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. Journal of Medical Virology. 52:1997;399-405.
54. Deseva M, Khudyakov Y E, Capriles F. Reduced antibody response reactivity to hepatitis C virus antigens in hemodialysis patients coinfected with hepatitis B virus. Clinical and Diagnostic Laboratory Immunology. 4:1997;639-642.
55. Zignego A L, Fontana R, Puliti S. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Archives of Virology. 142:1997;535-544.